Prostin VR: Treatment Information & Patient Guide

Introduction to Prostin VR

Prostin VR ( Alprostadil) is a naturally occurring prostaglandin used as a treatment for various medical conditions. It is a clear, colorless sterile solution for infusion, indicated for maintaining the patency of the ductus arteriosus in infants with congenital heart defects. Prostin VR is also used for the treatment of erectile dysfunction in males.

Medical Uses of Prostin VR

Prostin VR is primarily used as a palliative therapy for maintaining the patency of the ductus arteriosus in infants with congenital heart defects. It is a temporary treatment to keep the ductus arteriosus open until corrective or palliative surgery can be performed. In addition, Prostin VR is used for the treatment of erectile dysfunction in males by increasing blood flow into the penis to achieve and maintain an erection.

Prostin VR Pediatric

Prostin VR Pediatric is specifically formulated for use in infants and children. The dosage and administration guidelines for pediatric patients are different from those for adults. The safety and efficacy of Prostin VR in the pediatric population have been established through clinical trials, making it a valuable treatment option for infants with congenital heart defects.

Alprostadil

Alprostadil, the active ingredient in Prostin VR, is a synthetic version of a naturally occurring prostaglandin. It was first discovered in the 1930s and has since been developed and approved for various medical applications. Alprostadil works by relaxing smooth muscle and increasing blood flow, making it useful in the treatment of erectile dysfunction and maintaining the patency of the ductus arteriosus in infants.

Pharmacology

The pharmacokinetics of Prostin VR involve rapid absorption, distribution throughout the body, metabolism primarily in the lungs, and excretion through the kidneys. The pharmacodynamics of Alprostadil involve its interaction with specific receptors on the surface of cells, leading to relaxation of smooth muscle and increased blood flow. A study published in the British Journal of Clinical Pharmacology provides a detailed overview of the pharmacology of Alprostadil.

Formulation and Presentation

Prostin VR is available as a sterile solution for infusion. It is a clear, colorless solution supplied in glass ampoules containing 500 micrograms/mL of Alprostadil. Each box contains 5 ampoules of Prostin VR.

Excipient and Composition

In addition to the active ingredient Alprostadil, Prostin VR contains anhydrous ethanol as an excipient. The anhydrous ethanol content is 790 mg/mL, which is equivalent to 79% w/v. This information is important for healthcare professionals to consider when administering Prostin VR to patients.

Dosage and Administration

The recommended dosage of Prostin VR varies depending on the condition being treated. For maintaining the patency of the ductus arteriosus in infants, the initial recommended dose is 0.05 to 0.1 micrograms/kg/minute, adjusted according to response. For the treatment of erectile dysfunction, the recommended dose is 1.25 to 60 micrograms administered intracavernosally. Detailed dosage and administration guidelines can be found in the Prostin VR product monograph.

Contraindications and Precautions

Prostin VR is contraindicated in patients with known hypersensitivity to Alprostadil or any of the excipients. It should be used with caution in patients with cardiovascular disorders, respiratory disorders, or a history of priapism. Healthcare professionals should review the full list of contraindications and precautions before administering Prostin VR to patients.

Side Effects and Adverse Reactions

The most common side effects associated with Prostin VR include fever, diarrhea, jitteriness, hypotension, and rash. Serious adverse reactions, such as apnea, bradycardia, and hypotension, have been reported in infants receiving Prostin VR. Patients should be monitored closely for any signs of adverse reactions, and healthcare professionals should report any suspected adverse reactions to the appropriate regulatory authorities.

Clinical Trials and Efficacy

The efficacy and safety of Prostin VR have been demonstrated in various clinical trials. A randomized controlled trial published in the Journal of Pediatrics showed that Prostin VR was effective in maintaining the patency of the ductus arteriosus in infants with congenital heart defects. Another clinical trial published in the Journal of Sexual Medicine demonstrated the efficacy of Alprostadil in the treatment of erectile dysfunction.

Interactions with Other Medications

Prostin VR may interact with other medications, including anticoagulants, antihypertensives, and medications that affect liver enzyme activity. Healthcare professionals should review a patient’s complete medication history before administering Prostin VR to avoid potential drug interactions.

Patient Information

Patients and caregivers should be provided with comprehensive information about Prostin VR, including its uses, dosage, administration, side effects, and precautions. Patients should be instructed to report any adverse reactions to their healthcare provider immediately. The Pfizer Medical Information Patient Information Page provides valuable resources for patients and caregivers.

Regulatory and Approval History

Prostin VR was first approved by the U.S. Food and Drug Administration (FDA) in 1981 for the treatment of erectile dysfunction. It was subsequently approved for the maintenance of ductus arteriosus patency in infants with congenital heart defects. The regulatory and approval history of Prostin VR may vary in different countries and regions.

Pfizer Medical Information

Pfizer is the manufacturer and distributor of Prostin VR. Healthcare professionals can access valuable resources and contact Pfizer Medical Information for any questions or concerns regarding the use of Prostin VR. The Pfizer Medical Information Contact Page provides contact details and additional resources for healthcare professionals.

Global and Regional Availability

The availability of Prostin VR may vary in different countries and regions. Healthcare professionals should consult their local regulatory authorities and Pfizer representatives for information on the availability and regulatory status of Prostin VR in their specific location.

Research and Development

Ongoing research is being conducted to explore new applications and formulations of Alprostadil. Researchers are investigating the potential use of Alprostadil in the treatment of other conditions, such as peripheral arterial disease and Raynaud’s phenomenon. The future of Prostin VR and Alprostadil in medical practice is promising, with the potential for new indications and improved formulations.